Literature DB >> 29078627

Anatomic bisegmentectomy for synchronous lung adenocarcinoma.

Arthur Vieira1, Paula Ugalde Figueroa1.   

Abstract

Modern thoracic surgery requires the ability to manage patients with ground glass opacities (GGO). However, due to the lack of a standardize approach in our institution these cases are discussed in the tumor board. We here present our therapeutic rationale in a case of a patient with multiple GGOs, who underwent an en-bloc anatomic bisegmentectomy as surgical treatment for a synchronous lung adenocarcinoma.

Entities:  

Keywords:  Lung; anatomic segmentectomy; bisegmentectomy; ground glass opacities (GGO); ground glass opacity; lung cancer

Year:  2017        PMID： 29078627      PMCID： PMC5638506          DOI： 10.21037/jovs.2017.03.20

Source DB:  PubMed          Journal:  J Vis Surg        ISSN： 2221-2965


  8 in total

Review 1.  Subsolid pulmonary nodule management and lung adenocarcinoma classification: state of the art and future trends.

Authors:  Myrna C B Godoy; Mylene T Truong; Bradley Sabloff; David P Naidich
Journal:  Semin Roentgenol       Date:  2013-10       Impact factor: 0.800

2.  A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L).

Authors:  Kenichi Nakamura; Hisashi Saji; Ryu Nakajima; Morihito Okada; Hisao Asamura; Taro Shibata; Shinichiro Nakamura; Hirohito Tada; Masahiro Tsuboi
Journal:  Jpn J Clin Oncol       Date:  2009-11-22       Impact factor: 3.019

3.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

Authors:  R J Ginsberg; L V Rubinstein
Journal:  Ann Thorac Surg       Date:  1995-09       Impact factor: 4.330

4.  Comparison of the surgical outcomes of thoracoscopic lobectomy, segmentectomy, and wedge resection for clinical stage I non-small cell lung cancer.

Authors:  H Nakamura; Y Taniguchi; K Miwa; Y Adachi; S Fujioka; T Haruki; Y Takagi; Y Yurugi
Journal:  Thorac Cardiovasc Surg       Date:  2011-04-08       Impact factor: 1.827

5.  Oncologic efficacy of anatomic segmentectomy in stage IA lung cancer patients with T1a tumors.

Authors:  James M Donahue; Christopher R Morse; Dennis A Wigle; Mark S Allen; Francis C Nichols; K Robert Shen; Claude Deschamps; Stephen D Cassivi
Journal:  Ann Thorac Surg       Date:  2011-12-30       Impact factor: 4.330

6.  A case-matched study of anatomical segmentectomy versus lobectomy for stage I lung cancer in high-risk patients.

Authors:  Antonio E Martin-Ucar; Apostolos Nakas; John E Pilling; Kevin J West; David A Waller
Journal:  Eur J Cardiothorac Surg       Date:  2005-04       Impact factor: 4.191

Review 7.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

8.  Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis.

Authors:  Amgad El-Sherif; William E Gooding; Ricardo Santos; Brian Pettiford; Peter F Ferson; Hiran C Fernando; Susan J Urda; James D Luketich; Rodney J Landreneau
Journal:  Ann Thorac Surg       Date:  2006-08       Impact factor: 4.330
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.